Clik here to view.
Astellas Research & Development Meeting Highlights
TOKYO Astellas Pharma Inc. (Tokyo: 4503, President and CEO: Yoshihiko Hatanaka, “the Company”) announced that it is holding a research and development (R&D) meeting for securities analysts,...
View ArticleClik here to view.
Clik here to view.
CRISPRライセンシングのニーズに応えるMPEG LAイニシアチブ
デンバー （ビジネスワイヤ） — ライセンシングの世界的リーダー企業MPEG LAは本日、細胞DNAを迅速に低コストで編集できる画期的技術CRISPRをめぐり、効率的なワンストップ代替ライセンス手段のニーズに応えるイニシアチブを発表しました。一部のCRISPR特許は現在、米国特許商標庁にて多様な特許所有者と特許出願者の間で抵触審査手続き（No. 106048）の対象となっています。 MPEG...
View ArticleClik here to view.
Provision Healthcare的ProNova SC360质子治疗系统获得FDA核准
田纳西州诺克斯维尔 (美国商业资讯) — Provision Healthcare的研发和制造分支ProNova Solutions的SC360质子治疗系统已获得FDA 510(k)核准，该核准距研发启动仅有4年时间。这是首台也是唯一一台能够从所有角度治疗患者而无需移动患者的紧凑型360度笔尖束扫描质子治疗系统，实现了最高效的临床工作流程，提高了治疗精度和患者舒适性。...
View ArticleClik here to view.
KOREAN TL PLASTIC SURGERY, Everyone Has the Right to Look Beautiful; Useful...
SEOUL, South Korea TL’s SMAS LIFTING is the best beauty treatment procedure to restore your youth. The difficult-to-erase sign of aging disturbs women to create a perfect look and makes them less...
View ArticleClik here to view.
Oxford Nanopore 宣布融资1亿英镑（1.26亿美元）
英国牛津 Oxford Nanopore Technologies 有限公司 （简称Oxford Nanopore）宣布在最近一轮融资中以普通股私人配售方式获得了1亿英镑（1.26亿美元）的投资。总部位于英国的Oxford Nanopore 科技公司研发并销售世界上唯一的便携式DNA/RNA测序仪。此轮融资的领投者包括新的投资方GT Healthcare Capital Partners...
View ArticleClik here to view.
神経栄養性角膜炎：ドンペが提出したCenegermin点眼薬（Oxervate®）の市販承認申請をEMAが受理
ミラノ — （ビジネスワイヤ） — バイオ医薬品企業のドンペは、欧州医薬品庁（EMA）に提出した点眼薬Oxervate®の登録申請が受理されたと発表しました。Oxervate®は中等度および重度の神経栄養性角膜炎の成人患者を治療する医薬品です。...
View ArticleClik here to view.
プロビジョン・ヘルスケアがProNova SC360陽子線治療システムのFDA承認を取得
米テネシー州ノックスビル （ビジネスワイヤ） — プロビジョン・ヘルスケアの子会社として研究・開発・製造を手掛けるプロノーバ・ソリューションズは、SC360陽子線治療システムの研究開発を開始してわずか4年で、FDAから...
View ArticleClik here to view.
韦伦氏集团为赢创(Evonik)收购Huber的二氧化硅业务提供咨询服务
伦敦 (美国商业资讯)–韦伦氏集团(The Valence Group)已为赢创(Evonik)以6.3亿美元收购J.M.Huber的二氧化硅（亦称“硅石”）业务提供咨询服务。...
View ArticleClik here to view.
Clik here to view.
Vyome Presents on the Development of the Dual Action Rational Therapeutics...
NEW DELHI Vyome Biosciences, a clinical-stage specialty biopharmaceutical company developing novel medicines for treating diseases caused by drug-resistance in the skin microbiome, will present two...
View ArticleClik here to view.
Acucela Secures Option to Exclusively Acquire Novel Retinal Technology
SEATTLE Acucela Inc. (“Acucela”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) that specializes in identifying and...
View ArticleClik here to view.
Pfizer and Astellas Announce Top-Line Results from Phase 4 PLATO Trial of...
NEW YORK & TOKYO Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE:4503) today announced the Phase 4 PLATO study, evaluating the efficacy and safety of continued treatment with XTANDI®...
View ArticleClik here to view.
Baxter to Expand Portfolio of Essential Generic Injectable Medicines with...
DEERFIELD, Ill. Baxter International Inc. (NYSE:BAX), a global leader in sterile medication production and delivery, today entered into a definitive agreement to acquire Claris Injectables Limited,...
View ArticleClik here to view.
Gyros Protein Technologies and Abacus ALS Sign Distribution Agreement
UPPSALA, Sweden Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, announced today that it has appointed...
View ArticleClik here to view.
Radiation Oncology Centres Launches Australia’s First Electronic...
BRISBANE, Australia Elekta (STO:EKTAB) On December 8, a female patient in her 60s became the first in the Australia / New Zealand region to receive electronic brachytherapy to treat her skin cancer...
View ArticleClik here to view.
Korea TL Plastic SurgeryNatural & Dramatic: Most Popular Facial Contouring...
SEOUL, South Korea Facial contouring or facial sculpting is a way in which you can change the contours of the face as well as making parts of your face smaller or larger and creating emphasis on the...
View ArticleClik here to view.
Completion of a Reserved Share Capital Increase of Median Technologies to...
SOPHIA ANTIPOLIS, France Regulatory News: Median Technologies (Paris:ALMDT), the Imaging Phenomics™ Company announced in a press release dated November 16th, 2016 that it had entered into an...
View ArticleClik here to view.
和铂医药全资收购全球医药行业核心技术平台，打造专注肿瘤免疫领域的世界顶级生物科技公司
美国马萨诸塞州剑桥、中国上海、荷兰鹿特丹 (美国商业资讯)– 和铂医药，一家总部位于中国的新创公司，今天宣布以现金加股权的方式收购总部位于荷兰的Harbour Antibodies BV公司，并将在此基础上，打造专注肿瘤免疫领域的世界顶级生物医药公司。新公司将运用其拥有全面专利保护的Harbour...
View ArticleClik here to view.
Harbour BioMed Acquires Harbour Antibodies to Create Global, Oncology-focused...
CAMBRIDGE, Mass. & SHANGHAI & ROTTERDAM, The Netherlands Harbour BioMed, a recently established Shanghai-based company, today announced it has acquired Harbour Antibodies BV for cash and an...
View Article